AzTrials
AzTrials

Very Preterm Infants Born < 30 Weeks of GestationQUSBINCT07358819

Quantitative 3D UltraSound Brain Imaging: Development of New Bedside Biomarkers to Better Predict Neurodevelopmental Outcomes in Preterm Infants

A study testing Cranial ultrasound, Brain MRI and PARCA-R questionnaire in people with Very Preterm Infants Born < 30 Weeks of Gestation, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Prematurity is a leading cause of neurodevelopmental disorders (NDDs) tightly associated with white matter damage, including punctate white matter lesions (PWMLs). Hence, an improved detection of brain injury early in life in infants born very preterm is a top priority to predict NDDs and therefore to assess potential… Read more about this study

Who is it for?
Ages 23 to 35 weeks
What is being tested?
Cranial ultrasound, Brain MRI and PARCA-R questionnaire
Type of treatment
Surgery or procedure
How many people
360 participants
Where
1 siteFrance
Study dates
Apr 2026to Apr 2031
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 23 to 35 weeks
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Very preterm infants delivered (either inborn or outborn) between 23+0 and 29+6 weeks of gestation
  • Informed written consent of the holders of parental authority.

Who cannot join

  • Admission for palliative care
  • Chromosomal aberrations and major malformations evidenced after birth Major malformations
  • Chromosomal aberrations
  • No social security coverage

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

France1 site
  • Hôpital Cochin Port-Royal, APHP Centre

    Paris, Île-de-France Region, 75014

    Olivier BAUD, MD, PhD, 01 58 41 24 23 ext. +33, olivier.baud@aphp.fr

Other trials in France

About this study

Prematurity is a leading cause of neurodevelopmental disorders (NDDs) tightly associated with white matter damage, including punctate white matter lesions (PWMLs). Hence, an improved detection of brain injury early in life in infants born very preterm is a top priority to predict NDDs and therefore to assess potential neuroprotective strategies and implement early interventions. 3D and quantitative tools at the bedside using ultrasound are expected to better detect and quantify not only PWMLs but also other brain structures with promising prognostic value to predict NDDs at 2 years of age.

Read the detailed description

Rationale :

Prematurity is a leading cause of neurodevelopmental disorders (NDDs). In Europe, 10% of the 50 000 children born very preterm will develop cerebral palsy and 35% will experience persistent cognitive and neuropsychiatric disorders, including autism, requiring long-term health care support. NDDs following preterm birth are tightly associated with white matter damage, including punctate white matter lesions (PWMLs), a promising marker of subsequent NDDs affecting up to 24% of very preterm infants. Hence, an improved detection of brain injury early in life in infants born very preterm is a top priority to predict NDDs and therefore to assess potential neuroprotective strategies and implement early interventions. Magnetic Resonance Imaging (MRI) is the gold standard to assess white matter integrity and has revealed an association between thalamus structure, ventricular dilatation, white matter damage, and NDDs at preschool age in infants born very preterm. However, it suffers from limited accessibility, low portability, and high sensitivity to motion artifacts mitigating its value for screening in all preterm infants at risk of NDDs. Conversely, conventional 2D cranial ultrasonography (cUS) is a tool widely used in neonatal intensive care units to prospectively screen brain lesions through the anterior fontanel. However, while suitable to detect severe lesions observed in 4-5% of very premature infants only, it remains less reliable for the comprehensive detection of PWMLs despite recent improvements. Hence, 3D and quantitative tools at the bedside using ultrasound must be developed to automatically detect and quantify not only PWMLs but also other brain structures with promising prognostic value.

Main objective:

Identifying new early imaging biomarkers to predict NDDs at 2 years of age.

Primary endpoint:

Correlation between 3D quantification of PWMLs burden collected between day 3±1 and day 21±3, and results of Bayley Scale assessment, 4th edition, French edition (2022) at 2 years of age and the Parent Report of Children's Abilities-Revised (PARCA-R) questionnaire, which identifies preterm children at risk for developmental delays at 24 months of age.

Secondary objectives:

  • Developing a processing pipeline allowing the reconstruction of 3D cUS volume \& automatic detection and segmentation algorithms based on deep learning methods.
  • Validating these models to detect PWMLs, \& segment thalami and cerebral ventricular system (CVS).
  • Correlating thalami and CVS 3D longitudinal volumes in very preterm infants with \& without PWMLs

Secondary endpoints:

  • Longitudinal cUS data will allow the generation of standard growth curves for thalami and CVS volumes, stratified by sex and dependent on the concurrent detection of PWMLs.
  • Correlation between 3D quantification of PWMLs burden collected between day 3±1 and day 21±3, and results of the Parent Report of Children's Abilities-Revised (PARCA-R) questionnaire. 3D quantification of PWMLs and other 3D cUS tissue segmentations generated using new algorithms developed in WP3 as predictors of (i) MRI findings at term and (ii) neurodevelopmental outcomes at 2 years of age.

Impact :

This project will improve the quality of care by extending advanced quantitative brain imaging to all very preterm infants and improving the early diagnosis of brain injury. It is also expected to promote personalized medicine approaches and support translational research in neuroprotection through the development of new biomarkers for brain injury. Socio-economic impacts include cost reduction through early identification of at-risk children and timely interventions to prevent severe NDD. QUSBI will also have a significant impact on family support.

Being tested
Cranial ultrasound, Brain MRI, PARCA-R questionnaire
Keywords
Very preterm infants, White matter lesions, Neurodevelopment, 3D Cranial Ultrasound, Artificial intelligence, Prediction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cranial ultrasoundRadiation

    Dynamic recording of cranial ultrasound assessment with AI-assisted post-processing for brain segmentation at day 3±1, day 8±2, day 21±3, 36 weeks of postmenstrual age, and term equivalent age using bedside cUS.

  • Brain MRIRadiation

    Brain MRI at term equivalent of age for all neonates (considered as standard of care for those born before 28 weeks of gestation)

  • PARCA-R questionnaireOther

    Parent Report of Children's Abilities-Revised (PARCA-R) questionnaire at 2 years

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Identifying new early imaging biomarkers to predict NDDs at 2 years of age.

    Correlation between 3D quantification of PWMLs burden, and results of Bayley Scale assessment, at 2 years of age and the Parent Report of Children's Abilities-Revised (PARCA-R) questionnaire, which identifies preterm children at risk for developmental delays at 24 months of age.

    Measured: 2 years

Secondary outcomes (3)
  1. Developing a processing pipeline allowing the reconstruction of 3D cUS volume & automatic detection and segmentation algorithms based on deep learning methods.

    Longitudinal cUS data will allow the generation of standard growth curves for thalami and CVS volumes, stratified by sex and dependent on the concurrent detection of PWMLs

    Measured: Between day 3±1 and day 21±3

  2. Validating these models to detect PWMLs, & segment thalami and cerebral ventricular system (CVS).

    Correlation between 3D quantification of PWMLs burden collected between between day 3±1 and day 21±3 , day 3±1 and term equivalent age, and results of the Parent Report of Children's Abilities-Revised (PARCA-R) questionnaire.

    Measured: 2 years

  3. Correlating thalami and CVS 3D longitudinal volumes in very preterm infants with & without PWMLs

    3D quantification of PWMLs and other 3D cUS tissue segmentations generated using new algorithms developed in WP3 as predictors of (i) MRI findings at term and (ii) neurodevelopmental outcomes at 2 years of age

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Jan 2026
  2. Study startApr 2026 (estimated)
  3. Primary completionDec 2026 (estimated)
  4. Study completionApr 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
360 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07358819
Sponsor's protocol ID
APHP251518
Other IDs
IDRCB
Acronym
QUSBI
Status last verified
Feb 2026
First submitted
14 Jan 2026
Last updated
18 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Cranial ultrasound, Brain MRI and PARCA-R questionnaire in people with Very Preterm Infants Born < 30 Weeks of Gestation, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 18 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Olivier BAUD, MD, PhD (01 58 41 24 23 ext. +33, olivier.baud@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Identifying new early imaging biomarkers to predict NDDs at 2 years of age. (time frame: 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in